This conclusion was reached from cell-based experimentation focused on the response of the stem cell marker prominin-1, the chemotherapeutic target ICAM-1 and the alternative expression profiles of the lncRNAs PARTICLE and GAS5 within this in vitro GBM microenvironment [26]. This evidence concerns the gene PROM1 and glioblastoma.